UPLIZNA 판매 예측 및 시장 규모 분석(2034년)

Key Factors Driving UPLIZNA Growth

1. Strong commercial growth trajectory post-acquisition by Amgen

• UPLIZNA generated ~$379 million in 2024 sales, reflecting ~40% YoY growth (Amgen financial disclosures following the Horizon acquisition).
• Growth accelerated after Amgen acquired Horizon Therapeutics (2023), expanding commercialization reach.
• Strong sales momentum and backing by a large pharma company enable:
• Expanded global access
• Increased physician awareness
• Faster market penetration

2. Proven efficacy in neuromyelitis optica spectrum disorder (NMOSD)

• In the pivotal N-MOmentum Phase II/III trial:
• ~77% reduction in risk of NMOSD attacks vs placebo
• Significant reduction in disability progression (published in peer-reviewed literature)
• Approved for anti-AQP4 antibody-positive NMOSD, a severe autoimmune disease.
• Strong relapse prevention (clinically meaningful endpoint) drives:
• High physician confidence
• Long-term chronic use
• Favorable reimbursement

3. Unique CD19-targeting mechanism (broader B-cell depletion)

• UPLIZNA is a humanized monoclonal antibody targeting CD19, leading to broad B-cell depletion, including plasmablasts and some plasma cells.
• Differentiates from CD20 therapies (e.g., rituximab) which target a narrower B-cell population.
• Mechanistic advantage supports:
• Potential deeper disease control
• Positioning in patients with inadequate response to CD20 therapies

4. Expansion into IgG4-related disease (major growth catalyst)

• UPLIZNA received FDA approval in 2024 for IgG4-related disease (IgG4-RD), a rare systemic fibro inflammatory condition (Amgen press release).
• IgG4-RD represents a broader and less penetrated patient population compared to NMOSD.

5. Favorable dosing schedule and convenience

• Administered as two initial infusions followed by maintenance dosing every 6 months.
• Infrequent dosing improves:
• Patient compliance
• Convenience vs therapies requiring more frequent infusions
• Supports long-term adherence and sustained revenue per patient.

6. High unmet need in rare autoimmune diseases (orphan advantage)

• NMOSD and IgG4-RD are rare but severe diseases with:
• High relapse burden
• Limited targeted therapies historically
• Orphan drug positioning enables:
• Premium pricing
• Rapid adoption in specialist centers
• Strong reimbursement support

UPLIZNA Recent Developments

In February 2026, Amgen announced the European Commission (EC) approved UPLIZNA (Inebilizumab) as an add-on treatment to standard therapy for adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offers patients a new, targeted treatment option with the potential for long-term disease control through twice-yearly maintenance dosing, following two initial loading doses.

"UPLIZNA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of UPLIZNA for approved indication like Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus in the 7MM. A detailed picture of UPLIZNA's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the UPLIZNA for approved and potential indications. The UPLIZNA market report provides insights about UPLIZNA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current UPLIZNA performance, future market assessments inclusive of the UPLIZNA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of UPLIZNA sales forecasts, along with factors driving its market.

UPLIZNA Drug Summary

UPLIZNA is a humanized afucosylated IgG1 monoclonal antibody developed by Horizon Therapeutics (acquired by Amgen), FDA-approved in 2020 for neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adults, with subsequent approvals for immunoglobulin G4-related disease (IgG4-RD) and, as of late 2025, anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive generalized myasthenia gravis (gMG) in adults. It targets CD19, a B-cell surface antigen, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and phagocytosis to deplete CD19-positive B cells-including plasmablasts and plasma cells-thereby reducing pathogenic autoantibody production driving inflammation, relapses, and tissue damage in these rare autoimmune conditions. Administered intravenously as two 300 mg infusions 2 weeks apart, followed by 300 mg every 6 months, it offers convenient twice-yearly maintenance dosing after loading, though it carries boxed warnings for progressive multifocal leukoencephalopathy (PML) and hepatitis B reactivation, with common side effects including urinary tract infections, arthralgia, headache, and nausea. The report provides UPLIZNA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the UPLIZNA Market Report

The report provides insights into:

• A comprehensive product overview including the UPLIZNA MoA, description, dosage and administration, research and development activities in approved indications like Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus.
• Elaborated details on UPLIZNA regulatory milestones and other development activities have been provided in UPLIZNA market report.
• The report also highlights UPLIZNA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The UPLIZNA market report also covers the patents information, generic entry and impact on cost cut.
• The UPLIZNA market report contains current and forecasted UPLIZNA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The UPLIZNA market report also features the SWOT analysis with analyst views for UPLIZNA in approved and potential indications.

Methodology:

The UPLIZNA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

UPLIZNA Analytical Perspective by DelveInsight

• In-depth UPLIZNA Market Assessment

This UPLIZNA sales market forecast report provides a detailed market assessment of UPLIZNA for approved indication like Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted UPLIZNA sales data uptil 2034.

• UPLIZNA Clinical Assessment

The UPLIZNA market report provides the clinical trials information of UPLIZNA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

UPLIZNA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

UPLIZNA Market Potential & Revenue Forecast

• Projected market size for the UPLIZNA and its key indications
• Estimated UPLIZNA sales potential (UPLIZNA peak sales forecasts)
• UPLIZNA Pricing strategies and reimbursement landscape

UPLIZNA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• UPLIZNA Market positioning compared to existing treatments
• UPLIZNA Strengths & weaknesses relative to competitors

UPLIZNA Regulatory & Commercial Milestones

• UPLIZNA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

UPLIZNA Clinical Differentiation

• UPLIZNA Efficacy & safety advantages over existing drugs
• UPLIZNA Unique selling points

UPLIZNA Market Report Highlights

• In the coming years, the UPLIZNA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The UPLIZNA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence UPLIZNA's dominance.
• Other emerging products for Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus are expected to give tough market competition to UPLIZNA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of UPLIZNA in approved and potential indications.
• Analyse UPLIZNA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted UPLIZNA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of UPLIZNA in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of UPLIZNA? How strong is UPLIZNA's clinical and commercial performance?
• What is UPLIZNA's clinical trial status in each individual indications such as Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the UPLIZNA Manufacturers?
• What are the key designations that have been granted to UPLIZNA for approved and potential indications? How are they going to impact UPLIZNA's penetration in various geographies?
• What is the current and forecasted UPLIZNA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of UPLIZNA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to UPLIZNA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is UPLIZNA? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. UPLIZNA Overview in approved indications like Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus

• 2.1. Product Detail
• 2.2. UPLIZNA Clinical Development
  • 2.2.1. UPLIZNA Clinical studies
  • 2.2.2. UPLIZNA Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. UPLIZNA Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging UPLIZNA Therapies)

5. UPLIZNA Market Assessment

• 5.1. UPLIZNA Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. UPLIZNA Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. UPLIZNA Market Size in the United States for approved and potential indications
  • 5.3.2. UPLIZNA Market Size in Germany for approved and potential indications
  • 5.3.3. UPLIZNA Market Size in France for approved and potential indications
  • 5.3.4. UPLIZNA Market Size in Italy for approved and potential indications
  • 5.3.5. UPLIZNA Market Size in Spain for approved and potential indications
  • 5.3.6. UPLIZNA Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. UPLIZNA Market Size in Japan for approved and potential indications

6. UPLIZNA SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options